BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 38.40
+0.05 (0.13%)
Dec 31, 2025, 2:31 PM CST
BioGend Therapeutics Market Cap
BioGend Therapeutics has a market cap or net worth of 4.78 billion as of December 31, 2025. Its market cap has increased by 6.90% in one year.
Market Cap
4.78B
Enterprise Value
4.27B
Revenue
212.43M
Ranking
n/a
PE Ratio
n/a
Stock Price
38.40
Market Cap Chart
Since June 18, 2019, BioGend Therapeutics's market cap has increased from 2.71B to 4.78B, an increase of 75.94%. That is a compound annual growth rate of 9.02%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 31, 2025 | 4.78B | 14.21% |
| Dec 31, 2024 | 4.18B | -11.18% |
| Dec 29, 2023 | 4.71B | 109.50% |
| Dec 30, 2022 | 2.25B | -18.50% |
| Dec 30, 2021 | 2.76B | -22.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 238.84B |
| PharmaEssentia | 179.19B |
| Lotus Pharmaceutical | 74.95B |
| Heron Neutron Medical | 70.42B |
| Bora Pharmaceuticals Co., LTD. | 60.90B |
| Lin BioScience | 33.13B |
| Lumosa Therapeutics | 31.84B |
| Center Laboratories | 29.26B |